Dr. Zoubeidi awarded CIHR Project Grant

Date Posted: 
Dr. Zoubeidi

Dr. Amina Zoubeidi has been awarded a five-year CIHR Project grant in the Fall 2019 competition, with her proposal receiving a score of 96%. 

The role of the lineage oncogene ASCL1 in treatment-induced neuroendocrine prostate cancer
Principal Investigator: Dr. Amina Zoubeidi
Co-investigators: Dr. Alastair Davies and Dr. Faraz Hach

Prostate tumours are addicted to the androgen receptor (AR) for growth and survival. Capitalizing on this inherent weakness, potent drugs have been developed to “turn off” the AR and starve cancer cells of fuel. These therapies are widely used in the clinic and have undoubtedly benefited patient survival; however, they are merely palliative and no patients are cured. Alarmingly, nearly 25% of patients progress to a highly aggressive and deadly form of prostate cancer, called neuroendocrine prostate cancer (NEPC), where treatment remains decades old toxic chemotherapy and survival is measured in months.

Our research is focused on uncovering how prostate tumours evolve into NEPC following AR targeted therapy. We discovered that the transition to NEPC is orchestrated by ASCL1, a pro-neural protein that changes the structure of DNA to allow a prostate cancer cell to turn on neuronal genes and take on the identity of a neuroendocrine cell. In the current proposal, we aim to decipher the role of ASCL1 in altering the structure of DNA and its impact on treatment resistance and the transformation to NEPC. This work will advance our understanding of how prostate tumours evade therapy by transitioning to NEPC, and inform future therapeutic strategies to benefit patients with aggressive prostate cancer.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.


Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 


Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov